Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Mediators of Inflammation-Driven Expansion, Trafficking, and Function of Tumor-Infiltrating MDSCs.

Tannenbaum CS, Rayman PA, Pavicic PG, Kim JS, Wei W, Polefko A, Wallace W, Rini BI, Morris-Stiff G, Allende DS, Hamilton T, Finke JH, Diaz-Montero CM.

Cancer Immunol Res. 2019 Oct;7(10):1687-1699. doi: 10.1158/2326-6066.CIR-18-0578. Epub 2019 Aug 22.

PMID:
31439615
2.

Unfolded Protein Response Differentially Regulates TLR4-Induced Cytokine Expression in Distinct Macrophage Populations.

Zhang L, Pavicic PG Jr, Datta S, Song Q, Xu X, Wei W, Su F, Rayman PA, Zhao C, Hamilton T.

Front Immunol. 2019 Jun 21;10:1390. doi: 10.3389/fimmu.2019.01390. eCollection 2019.

3.

Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma.

Tzeng A, Diaz-Montero CM, Rayman PA, Kim JS, Pavicic PG Jr, Finke JH, Barata PC, Lamenza M, Devonshire S, Schach K, Emamekhoo H, Ernstoff MS, Hoimes CJ, Rini BI, Garcia JA, Gilligan TD, Ornstein MC, Grivas P.

Target Oncol. 2018 Oct;13(5):599-609. doi: 10.1007/s11523-018-0595-9.

PMID:
30267200
4.

Evaluation of T cell infiltration in matched biopsy and nephrectomy samples in renal cell carcinoma.

Zahoor H, Pavicic PG Jr, Przybycin C, Ko J, Stephens L, Radivoyevitch T, Jia X, Diaz-Montero CM, Finke J, Rayman PA, Gilligan TD, Grivas P, Ornstein M, Garcia JA, Rini BI.

Medicine (Baltimore). 2018 Sep;97(37):e12344. doi: 10.1097/MD.0000000000012344.

5.

Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial.

Rini BI, Dorff TB, Elson P, Rodriguez CS, Shepard D, Wood L, Humbert J, Pyle L, Wong YN, Finke JH, Rayman PA, Larkin JM, Garcia JA, Plimack ER.

Lancet Oncol. 2016 Sep;17(9):1317-24. doi: 10.1016/S1470-2045(16)30196-6. Epub 2016 Aug 3.

PMID:
27498080
6.

Modification of the tumor microenvironment as a novel target of renal cell carcinoma therapeutics.

Finke JH, Rayman PA, Ko JS, Bradley JM, Gendler SJ, Cohen PA.

Cancer J. 2013 Jul-Aug;19(4):353-64. doi: 10.1097/PPO.0b013e31829da0ae. Review.

7.

Myeloid-derived suppressor cells adhere to physiologic STAT3- vs STAT5-dependent hematopoietic programming, establishing diverse tumor-mediated mechanisms of immunologic escape.

Cohen PA, Ko JS, Storkus WJ, Spencer CD, Bradley JM, Gorman JE, McCurry DB, Zorro-Manrique S, Dominguez AL, Pathangey LB, Rayman PA, Rini BI, Gendler SJ, Finke JH.

Immunol Invest. 2012;41(6-7):680-710. doi: 10.3109/08820139.2012.703745. Review.

8.

Inhibition of metastasis by HEXIM1 through effects on cell invasion and angiogenesis.

Ketchart W, Smith KM, Krupka T, Wittmann BM, Hu Y, Rayman PA, Doughman YQ, Albert JM, Bai X, Finke JH, Xu Y, Exner AA, Montano MM.

Oncogene. 2013 Aug 15;32(33):3829-39. doi: 10.1038/onc.2012.405. Epub 2012 Sep 10.

9.

GD3, an overexpressed tumor-derived ganglioside, mediates the apoptosis of activated but not resting T cells.

Sa G, Das T, Moon C, Hilston CM, Rayman PA, Rini BI, Tannenbaum CS, Finke JH.

Cancer Res. 2009 Apr 1;69(7):3095-104. doi: 10.1158/0008-5472.CAN-08-3776. Epub 2009 Mar 10.

10.

Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients.

Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, Golshayan A, Rayman PA, Wood L, Garcia J, Dreicer R, Bukowski R, Finke JH.

Clin Cancer Res. 2009 Mar 15;15(6):2148-57. doi: 10.1158/1078-0432.CCR-08-1332. Epub 2009 Mar 10.

11.

Mechanisms of immune dysfunction in renal cell carcinoma.

Derweesh IH, Tannenbaum CS, Rayman PA, Finke JH.

Cancer Treat Res. 2003;116:29-51. Review. No abstract available.

PMID:
14650824

Supplemental Content

Loading ...
Support Center